nafronyl

Summary

Alias: merck lipha sant brand 2 of naftidrofuryl oxalate, praxilene, nafti ratiopharm, abbott brand of naftidrofuryl oxalate, naftilong, azupharma brand of naftidrofuryl oxalate, hexal brand of naftidrofuryl oxalate, nafti puren, ls 121, ct arzneimittel brand of naftidrofuryl oxalate, lipha brand of naftidrofuryl oxalate, faes brand of naftidrofuryl oxalate, merck lipha sant brand 1 of naftidrofuryl oxalate, merck brand of nafronyl oxalate, alpharma brand of naftidrofuryl oxalate, artocoron, nafti von ct, praxilne, nafronyl oxalate, di actane, gvatran, naftifurin oxalate, menarini brand of naftidrofuryl oxalate, azunaftil, ratiopharm brand of naftidrofuryl oxalate, thrabel brand of naftidrofuryl oxalate, dusodril, naftilux
Summary: A drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1310) It may also be an antagonist at 5HT-2 serotonin receptors.

Publications

  1. [Secondary prevention and conservative therapy of obliterative arteriosclerosis]
    Anna Landi
    Fóvárosi Szent István Kórház, IV Belgyógyászati Osztály, Budapest
    Orv Hetil 145:1035-43
  2. Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK
    Julian F Guest
    CATALYST Health Economics Consultants, Northwood, Middlesex, UK
    Curr Med Res Opin 21:817-26
  3. Can claudication be improved with medication?
    Michael S Conners
    Department of Vascular Surgery, Ochsner Clinic Foundation, New Orleans, LA 70121, USA
    Semin Vasc Surg 15:237-44
  4. Naftidrofuryl: a review of its use in the treatment of intermittent claudication
    David R Goldsmith
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 22:967-77
  5. [Idiopathic sudden sensorineural hearing loss. What's the appropriate management?]
    Olfa Ben Gamra
    Service ORL and Chirurgie Cervico Faciale, Hôpital Habib Thameur Tunis, Tunisie
    Tunis Med 85:839-42
  6. [Inpatient infusion treatment for acute tinnitus with and without adjuvant psychotherapeutic intervention. A comparison of psychological effectiveness]
    A Schildt
    Fachbereich Psychologie, Universität Hamburg
    HNO 54:781-91
  7. Reduction of endothelin-1 binding and inhibition of endothelin-1-mediated detrusor contraction by naftidrofuryl
    Robert C Calvert
    Department of Urology, Royal Free and University College Medical School, Royal Free Campus, Rowland Hill Street, London NW3 2PF
    Clin Sci (Lond) 103:459S-463S
  8. Findings of the Naftidrofuryl in Quality of Life (NIQOL) European study program
    F Spengel
    Klinik Feldafing, Feldafing, Germany
    Int Angiol 21:20-7
  9. Calcium oxalate deposition in renal allografts: morphologic spectrum and clinical implications
    Luan D Truong
    Department of Pathology, Renal Section, Baylor College of Medicine, The Methodist Hospital, Houston, TX, USA
    Am J Transplant 4:1338-44
  10. Naftidrofuryl exerts antiserotonergic but no endothelin-receptor blocking effects in AS4.1 cells, juxtaglomerular cells and isolated perfused rat kidneys
    Dierk Endemann
    Department of Medicine II, University of Regensburg, Regensburg, Germany
    J Cardiovasc Pharmacol 39:1-8

Scientific Experts

  • Julian F Guest
  • T S Tiong
  • Robert C Calvert
  • R Schindler
  • E Lucile White
  • Luan D Truong
  • Viktor Grünwald
  • H Kessler
  • Susan J Keam
  • A Schildt
  • Olfa Ben Gamra
  • Bruno Legallicier
  • David R Goldsmith
  • Anna Landi
  • P H Boeijinga
  • Evangelos Cholongitas
  • A Marconi
  • R Sternitzky
  • Dierk Endemann
  • Michael S Conners
  • J V Butler
  • F Spengel
  • S Zribi
  • Hajer Bhar
  • Chiraz Mbarek
  • Lamia Sghaier
  • Imen Ben Rejab
  • A El Khedim
  • Ines Hariga
  • Maguy Bromet-Petitd
  • Maguy Bromet Petitd
  • Stephane Barbier
  • Pierre Chretien
  • Florence Porte
  • Michel Godin
  • Jean Paul Fillastre
  • Laetitia Bolloni
  • Jean-Paul Fillastre
  • Thomas Kuhn
  • Thibaut Dupain
  • Keri Wellington
  • J F Nedelec
  • George V Papatheodoridis
  • M L Souan
  • A Boulmerka
  • L Staner
  • J P Macher
  • S Gamand
  • Anastasia Mavrogiannaki
  • M Mosnier
  • P Parot
  • C Gilles
  • R Luthringer
  • Emanuel Manesis
  • S Darquenne
  • Martin C Kammerl
  • Karl-Peter Ittner
  • F Liard
  • F Jung
  • E C Mulkerrin
  • P Lehert
  • Samuel R Money
  • G Pindur
  • C Mrowietz
  • Michael Fischereder
  • H Boccalon
  • T Brown
  • Mike Stubanus
  • Karl Peter Ittner
  • Frank Schweda

Detail Information

Publications20

  1. [Secondary prevention and conservative therapy of obliterative arteriosclerosis]
    Anna Landi
    Fóvárosi Szent István Kórház, IV Belgyógyászati Osztály, Budapest
    Orv Hetil 145:1035-43
    ..The results of clinical trials show a marked improvement of intermittent claudication by combination of preventive and therapeutic ways in majority of patients with peripheral arterial obliterative disease...
  2. Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK
    Julian F Guest
    CATALYST Health Economics Consultants, Northwood, Middlesex, UK
    Curr Med Res Opin 21:817-26
    ..Moreover, the acquisition cost of a drug should not be used as an indication of the cost effectiveness of a given method of care...
  3. Can claudication be improved with medication?
    Michael S Conners
    Department of Vascular Surgery, Ochsner Clinic Foundation, New Orleans, LA 70121, USA
    Semin Vasc Surg 15:237-44
    ..The efficacies, as well as common adverse reactions associated with current medications used to treat patients with intermittent claudication are reviewed...
  4. Naftidrofuryl: a review of its use in the treatment of intermittent claudication
    David R Goldsmith
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 22:967-77
    Naftidrofuryl (Praxilene) is a vasodilator that has been used in the treatment of intermittent claudication for >30 years in Europe to improve walking distance and provide symptomatic relief...
  5. [Idiopathic sudden sensorineural hearing loss. What's the appropriate management?]
    Olfa Ben Gamra
    Service ORL and Chirurgie Cervico Faciale, Hôpital Habib Thameur Tunis, Tunisie
    Tunis Med 85:839-42
    ..Recovery was observed mainly in patients with moderate (71.4%) and severe hearing deficiency (69.2%). CONCLUSION: Corticosteroids are the less controversed treatment of sudden sensorineural hearing loss...
  6. [Inpatient infusion treatment for acute tinnitus with and without adjuvant psychotherapeutic intervention. A comparison of psychological effectiveness]
    A Schildt
    Fachbereich Psychologie, Universität Hamburg
    HNO 54:781-91
    ..This study received one of the two scientific first prizes of the "German Tinnitus League"...
  7. Reduction of endothelin-1 binding and inhibition of endothelin-1-mediated detrusor contraction by naftidrofuryl
    Robert C Calvert
    Department of Urology, Royal Free and University College Medical School, Royal Free Campus, Rowland Hill Street, London NW3 2PF
    Clin Sci (Lond) 103:459S-463S
    ..Naftidrofuryl (Naf) (marketed under the trade name Praxilene) improves walking distance in patients with peripheral vascular disease, an effect which may be partially ..
  8. Findings of the Naftidrofuryl in Quality of Life (NIQOL) European study program
    F Spengel
    Klinik Feldafing, Feldafing, Germany
    Int Angiol 21:20-7
    ..These findings, taken together with evidence from previous studies that it improves treadmill walking distances, suggest that naftidrofuryl can play a useful role in the treatment of this condition...
  9. Calcium oxalate deposition in renal allografts: morphologic spectrum and clinical implications
    Luan D Truong
    Department of Pathology, Renal Section, Baylor College of Medicine, The Methodist Hospital, Houston, TX, USA
    Am J Transplant 4:1338-44
    ..CaOx deposition in renal allografts can be classified in different categories with distinctive morphologic features and clinical implications...
  10. Naftidrofuryl exerts antiserotonergic but no endothelin-receptor blocking effects in AS4.1 cells, juxtaglomerular cells and isolated perfused rat kidneys
    Dierk Endemann
    Department of Medicine II, University of Regensburg, Regensburg, Germany
    J Cardiovasc Pharmacol 39:1-8
    ..The present results suggest that naftidrofuryl is a potent antagonist of serotonin's renal effects, but has no endothelin receptor-blocking properties...
  11. Vitamin A metabolism is altered in brown Norway and long-Evans rats infused with naftidrofuryl or erythromycin intravenously
    Rainer Schindler
    Department of Human Nutrition and Food Science, Düsternbrooker Weg 17, Christian Albrechts University, D 24116 Kiel, Germany
    Int J Vitam Nutr Res 72:210-20
    ..003) secondary to naftidrofuryl exposure. Together our data suggest that clinically achievable concentrations of the drugs, given as a continuous infusion, produce aberrations in vitamin A metabolism...
  12. Effect of naftidrofuryl on intramuscular partial oxygen pressure (pO2) prior to, during and after physical load on the treadmill in apparently healthy subjects
    R Sternitzky
    Institute for Cardiovascular Research, Forststrasse 5, 01099 Dresden, Germany
    Clin Hemorheol Microcirc 27:185-91
    ..With 33.9+/-12.0 mmHg the mean minimum pO2 determined at the higher load level still ranges above the basal pO2 measured before the start of naftidrofuryl treatment...
  13. Nocturnal leg cramps in older people
    J V Butler
    Department of Medicine for the Elderly, University College Hospital and Merlin Park Hospital, Galway, Ireland
    Postgrad Med J 78:596-8
    ..In patients with severe symptoms, a trial of 4-6 weeks' treatment with quinine is probably still justified, but the efficacy of treatment should be monitored, for example using a sleep and cramp diary...
  14. Naftidrofuryl-induced liver injury
    Evangelos Cholongitas
    Am J Gastroenterol 98:1448-50
  15. Pharmacokinetics of naftidrofuryl in patients with renal impairment
    Bruno Legallicier
    Department of Nephrology, Rouen University Hospital, Rouen, France
    Arzneimittelforschung 55:370-5
    ..compare the pharmacokinetics of naftidrofuryl after single oral administration of a 200 mg naftidrofuryl tablet (Praxilene) in caucasian male and female subjects with renal impairment versus healthy volunteers...
  16. Naftidrofuryl-driven regulation of endothelial ICAM-1 involves nitric oxide
    A Marconi
    INSERM U506, Hôpital Paul Brousse, Villejuif, France
    Free Radic Biol Med 34:616-25
    ..Importantly, it also highlights a novel NOS II-dependent mechanism of action for naftidrofuryl...
  17. Characterization of the CNS effects of naftidrofuryl (Praxilène) by quantitative EEG and functional MRI: a study in healthy elderly subjects
    P H Boeijinga
    FORENAP Research Institute for Neuroscience, Pharmacology and Psychiatry, Rouffach, France
    Neuropsychobiology 48:160-8
    ..The results of the present study can be interpreted at the functional level that naftidrofuryl induced an improved level of vigilance or an increased capacity of alertness in healthy elderly subjects...
  18. Prognostic indicators of management of sudden sensorineural hearing loss in an Asian hospital
    T S Tiong
    Department of Surgery, Faculty Medicine and Health Sciences, University Malaysia Sarawak, Lot 77 Jalan Tun Zaidi Adruce, Kuching 93150, Sarawak, Malaysia
    Singapore Med J 48:45-9
    ..Further findings of note were the six audiogram patterns and the good prognostic indicators in patterns 1 and 4...
  19. A novel inhibitor of Mycobacterium tuberculosis pantothenate synthetase
    E Lucile White
    Southern Research Institute, Birmingham, AL 35205 5305, USA
    J Biomol Screen 12:100-5
    ..This coupled enzymatic reaction was used to screen 4080 compounds in a 96-well format. This discussion describes a novel inhibitor of PS that exhibits potential as an antimicrobial agent...